Medtronic faces patent suit; Covidien making moves in Minnesota;

 @FierceMedDev: Halt Medical snags $15M to launch uterine fibroid device. Story | Follow @FierceMedDev

@MarkHFierce: We at Fierce are gearing up for some major coverage of JPM13. The fun starts Monday in San Francisco. Editor's Corner | Follow @MarkHFierce

 @DamianFierce: Hologic is selling off one of the business units it acquired in last year's $3.8B Gen-Probe buy. News | Follow @DamianFierce

> Tech company Alisanos is suing Medtronic ($MDT), saying the devicemaker infringed on its patent with the Octopus Evolution heart-stabilization device. Article (sub. req.)

> Covidien ($COV) is growing in its competitors' backyard, consistently expanding its Twin Cities presence with M&A and organic development. News

> Minerva Surgical pulled in $20 million in new venture funding for an endometrial ablation system designed to treat heavy menstrual bleeding. Story

> Stentys says a study has shown that its self-apposing stents are superior to conventional balloon expandable stents as a treatment for severe heart attacks. Item

> BioPhotas picked up 510(k) clearance for Celluma, a light-based therapy for skin, joint and muscle conditions. Release

> Sensus Healthcare has raised $2.4 million to expand the use of its non-invasive device that treats non-melanoma skin cancers. Report

Biotech News

 @FierceBiotech: Slideshow: FDA Approvals of 2012. More | Follow @FierceBiotech

@RyanMFierce: $BIIB has filed for FDA approval of long-lasting clotting factor in hemophilia B, a new area for the biotech giant. More | Follow @RyanMFierce

> UCSD biotech spinoff snags $18M A round to advance RNAi drugs. Article

> Amicus jumps on upbeat data for Pompe drug. News

Pharma News

@FiercePharma: Here's evidence of Vivus growth expectations: New HQ space almost 3X the size of current offices. More | Follow @FiercePharma

 @EricPFierce: The FDA approved nearly a dozen new cancer drugs in 2012, but also drugs for erectile dysfunction weight-loss. Special Report | Follow @EricPFierce

 @AlisonBFierce: Eli Lilly will step up to the plate to defend against DES litigation. News | Follow @AlisonBFierce

> Analyst says Vivus buyout, partner best for Qsymia sales. Report

> Lilly betting B12 can protect blockbuster Alimta from generics. Article

> Abbott said to be looking at buying Bausch & Lomb. Story


Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,